البحث العلمي في دولة الإمارات

Teriflunomide Use for MS in GCC Countries

نُشرت في الأربعاء، 9 مارس 2022

Real-world effectiveness and safety profile of teriflunomide in the management of multiple sclerosis in the Gulf Cooperation Council countries: An expert consensus narrative review

With rising MS prevalence in GCC countries, experts convened to review real-world data on teriflunomide’s role in managing relapsing-remitting MS (RRMS). They recommend teriflunomide for patients aged 18+ with clinically isolated syndrome or RRMS, emphasizing cost-effectiveness, adherence, and safety. The consensus also considers cultural factors, monitoring requirements, and COVID-19 implications. This evidence-based guidance aims to support clinicians in daily practice, improving patient outcomes through tailored MS management strategies.

البحوث ذات الصلة

اعرف المزيد
Switching from Fingolimod/Natalizumab to Cladribine Without Rebound
الجمعة، 1 ديسمبر 2023

Switching from Fingolimod/Natalizumab to Cladribine Without Rebound

اعرف المزيد
اعرف المزيد
Adherence Challenges for High-Efficacy MS Therapies
الجمعة، 22 مايو 2020

Adherence Challenges for High-Efficacy MS Therapies

اعرف المزيد
اعرف المزيد
Living with MS: A Biopsychosocial Perspective
الثلاثاء، 17 أغسطس 2021

Living with MS: A Biopsychosocial Perspective